SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: yosi s who wrote (718)5/6/1998 7:20:00 AM
From: Gabe Fernandez  Respond to of 1491
 
a 50% improvement in the mortality rate is outstanding but also an improvement in the functional capabilities of the head injury victim is another factor that i am sure is being addressed by their research group ex head injury classification (Glaxo coma scale 6-7)what % of the surviving group achieved a good functional level. Probably enough time has not elapsed to determine this,but if functional improvement also occurs this drug may be an important breakthrough.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News